A Registry for Patients With Multifocal Ground Glass Opacities (GGOs)

Thoracic Surgery Oncology Group (TSOG) Protocol: Registry Trial of Active Surveillance for Multifocal Ground Glass Opacities (GGOs)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03802981

Enrollment

338

Registered

2019-01-14

Start date

2019-01-09

Completion date

2027-01-01

Last updated

2026-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Ground Glass Opacities (GGOs)

Brief summary

The purpose of this registry study is to actively monitor people with GGOs and collect information about them, so that investigators can learn more about these lesions and about the risk of developing lung cancer in study participants whose GGOs are being monitored in the active surveillance program.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age greater than 18 years * Have two or more GGOs on initial CT imaging * GGOs must be measure ≤3.0 cm and ≥0.6 cm in the greatest dimension * GGOs must be greater than half ground glass A biopsy is not necessary for inclusion in the trial. Biopsy of a GGO, even with a diagnosis of adenocarcinoma, does not necessarily preclude enrollment in this surveillance protocol. In other words, patients with a diagnosis of adenocarcinoma are still eligible, at the discretion of the clinician and/or investigator, if they meet the above criteria.

Exclusion criteria

* Patients who are actively undergoing lung cancer treatment or have a history of lung cancer, except for cases of completely resected pathologic stage IA nonsmall cell lung cancer (NSCLC). Patients with stage IA NSCLC and multiple GGOs can enroll in this active surveillance protocol after complete resection of the NSCLC and confirmation of stage on final pathologic assessment. * The presence of any solid lesion ≥0.6 cm suspicious for malignancy. * Patients who are actively undergoing treatment for other malignancies

Design outcomes

Primary

Measure	Time frame
lung cancer-specific survival	5 years

Countries

Canada, United States

Contacts

PRINCIPAL_INVESTIGATORJames Huang, MD

Memorial Sloan Kettering Cancer Center

Outcome results